Rezolute, Inc. (RZLT): Business Model Canvas [Apr-2026 Updated]

You're looking at Rezolute, Inc. (RZLT) right at its inflection point: moving from clinical trials to a commercial reality, and honestly, the whole story hinges on the pivotal Phase 3 data expected this December 2025. As an analyst who's seen this transition many times, I see a company burning cash-with a reported net loss burn of about $74.4 million-but holding a war chest of $167.9 million as of mid-2025 to get ersodetug to market for ultra-rare hyperinsulinism. This Business Model Canvas breaks down exactly how they plan to turn that cash and the Breakthrough Therapy Designation into future product sales, especially since they posted $0 in product revenue for fiscal year 2025. Dive in to see the key activities and customer segments that must fire perfectly for this high-stakes bet to pay off.

Rezolute, Inc. (RZLT) - Canvas Business Model: Key Partnerships

You're hiring before product-market fit, which means your key partnerships are the engine that keeps the clinical and financial wheels turning. For Rezolute, Inc., these relationships are critical for advancing ersodetug through pivotal trials and securing the capital needed to reach potential commercialization.

Clinical Research Organizations (CROs) for global Phase 3 trials

The execution of Rezolute, Inc.'s global Phase 3 trials relies heavily on the operational support from CROs. While specific CRO names aren't public in the latest filings, the scale of the work is quantifiable. The sunRIZE study, evaluating ersodetug for congenital hyperinsulinism (HI), completed enrollment with exactly 62 participants across multiple global sites. This required significant coordination, likely managed through one or more CRO partners. The topline data readout for this trial is anticipated in December 2025.

For the tumor HI indication, Rezolute, Inc. secured FDA alignment in August 2025 for a streamlined Phase 3 upLIFT study, which requires as few as 16 participants. This streamlined approach, which removed the need for a double-blind randomized placebo-controlled trial, suggests a partnership structure focused on efficient, targeted patient access, possibly leveraging existing investigator sites from prior work.

Key Opinion Leaders (KOLs) and clinical investigators at major medical centers

The success of the sunRIZE trial, which included approximately 15 percent of its 62 participants from U.S. sites, speaks to strong engagement with clinical investigators at key medical centers. The data presented at the Endocrine Society (ENDO 2025) meeting reflects the work done in collaboration with these clinical experts. The company also strengthened its leadership by appointing rare disease commercial leader Erik Harris to its Board of Directors in March 2025, bringing in high-level industry expertise to guide future commercial strategy.

Contract Manufacturing Organizations (CMOs) for ersodetug production

Advancing ersodetug into late-stage trials and preparing for potential commercialization necessitates reliable CMO partnerships for the fully human monoclonal antibody. Research and development expenses for fiscal year 2025 totaled $61.5 million, an increase from $55.7 million in fiscal year 2024, with manufacturing costs for ersodetug cited as a contributing factor to this rise. This spend reflects ongoing, scaled-up production activities necessary to supply both the ongoing sunRIZE trial and the initiating upLIFT trial.

Patient advocacy groups for hyperinsulinism (HI) awareness and recruitment

Recruitment for rare disease trials like sunRIZE, which targeted patients with congenital HI, is heavily dependent on relationships with patient advocacy groups. The completion of enrollment for sunRIZE with 62 participants demonstrates effective outreach to the underserved HI community. The company's focus is on treating hypoglycemia caused by all forms of HI, which broadens the potential patient base that advocacy groups represent.

Institutional investors providing capital for the $74.4 million net loss burn

The operational burn rate is clearly reflected in the financials, but the capital structure shows strong backing from institutional partners. Rezolute, Inc.'s full fiscal year 2025 net loss was $74.4 million, up from $68.5 million in fiscal year 2024. This loss was financed, in part, by a significant equity offering in April 2025 that raised approximately $90 million in gross proceeds. This capital infusion extended the cash runway to the middle of 2027.

Key partners in this financing included prominent institutional players:

• Federated Hermes Kaufmann Funds, which also holds a significant stake, with Federated Hermes Inc. owning 13% of shares outstanding as of July 1, 2025.
• Blackstone Multi-Asset Investing.
• Great Point Partners, LLC.

Overall, institutional investors and hedge funds owned approximately 82.97% of Rezolute, Inc.'s stock as of late 2025, indicating a high degree of reliance on this sophisticated investor base.

The next concrete action item is for the Clinical Operations team to finalize data lock procedures for the sunRIZE trial by the end of November to ensure the December 2025 topline readout.

Rezolute, Inc. (RZLT) - Canvas Business Model: Key Activities

You're looking at the core engine driving Rezolute, Inc. right now-the activities necessary to get ersodetug across the finish line for two distinct, rare forms of hyperinsulinism (HI). It's all about execution on the clinic, manufacturing readiness, and setting up the commercial groundwork before the first dollar of revenue hits the books.

Executing and completing the Phase 3 sunRIZE trial for congenital HI

The sunRIZE trial, a Phase 3, multicenter, double-blind, randomized, controlled safety and efficacy registrational study for congenital HI, has hit a major milestone. Enrollment is complete. You should note that Rezolute, Inc. actually exceeded its enrollment target, bringing in 62 participants against a goal of 56. Approximately 15 percent of these participants were enrolled from U.S. sites. The company has FDA alignment that this study meets the registrational requirements needed for a Biologics License Application (BLA) filing and review. The baseline characteristics of the enrolled population are concrete: the average age is 3.4 years, with 35% being less than 2 years old. These patients were experiencing an average of 15 hypoglycemia events per week, with 19% daily time in hypoglycemia, even though 95% were already taking one or more standard-of-care (SOC) treatments. The key activity now is the data analysis, with topline results expected in December 2025.

Advancing the streamlined Phase 3 upLIFT trial for tumor HI

For tumor HI, Rezolute, Inc. secured a significant win with the FDA in August 2025, aligning on a much more streamlined development path. This means the planned double-blind randomized placebo-controlled trial component was removed. The pivotal study, upLIFT, is now a truncated, single-arm, open-label Phase 3 study enrolling up to 16 hospitalized participants. Enrollment is currently underway, and the data from the sunRIZE trial is confirmed to serve as confirmatory clinical evidence for this indication. You can expect topline results from the upLIFT trial in the second half of 2026.

Here's a quick look at the status of these two critical Phase 3 activities:

Manufacturing and supply chain development for ersodetug (RZ358)

Developing the supply chain for ersodetug is a major operational focus, reflected in the spending. Full fiscal year 2025 Research and Development (R&D) expenses were $61.5 million, an increase from $55.7 million in fiscal year 2024. These R&D costs included expenditures for manufacturing costs for ersodetug. For the fourth quarter of fiscal 2025, R&D expenses hit $20.9 million, up from $19.1 million the prior year. It's worth noting that in the first quarter of fiscal 2026, manufacturing costs for ersodetug actually decreased compared to the same period a year ago, suggesting some initial scale-up hurdles might be clearing.

Regulatory submissions and dialogue with the FDA and EMA for approval

The regulatory work is heavily focused on leveraging designations to expedite review. Rezolute, Inc. secured Breakthrough Therapy Designation (BTD) from the FDA for tumor HI in May 2025, and also holds Orphan Drug Designation (ODD) for this indication. Furthermore, the FDA lifted partial clinical holds on ersodetug for congenital HI, concluding that observed liver toxicity in rats was likely strain-specific and not relevant to humans. This cleared the path for U.S. inclusion in the sunRIZE study, which began in early 2025. The company is actively engaging with the FDA to move toward a BLA filing based on the sunRIZE data.

• FDA Breakthrough Therapy Designation granted for tumor HI: May 2025.
• FDA Orphan Drug Designation granted for tumor HI.
• FDA removed partial clinical holds for congenital HI study.
• FDA confirmed sunRIZE trial meets registrational requirements.

Building out the rare disease commercial infrastructure and launch strategy

To prepare for potential approval, Rezolute, Inc. is building out its commercial muscle. A key action was the appointment of Dr. Sunil Karnawat as Chief Commercial Officer in August 2025. Dr. Karnawat brings direct experience, having been responsible for leading key commercial functions in launching four ultra-rare disease products while at Ultragenyx. The company is currently pre-revenue in late 2025, but analysts forecast sales to potentially peak at over $1 billion across the first two target markets. This commercial build-out is reflected in the rising operational spend:

• Full Fiscal Year 2025 General and Administrative (G&A) expenses reached $18.4 million, up from $14.7 million in fiscal year 2024.
• Fourth Quarter Fiscal 2025 G&A expenses were $5.0 million, up from $4.0 million the prior year.

Financially, the company is funding these activities with a strong cash balance. Cash, cash equivalents, and investments were $167.9 million as of June 30, 2025, up from $127.1 million as of June 30, 2024. This provided a runway of approximately 2.25 years based on the burn rate at that time. The full fiscal year 2025 net loss widened to $74.4 million from a net loss of $68.5 million in fiscal year 2024. Finance: draft 13-week cash view by Friday.

Rezolute, Inc. (RZLT) - Canvas Business Model: Key Resources

You're looking at the core assets Rezolute, Inc. (RZLT) is banking on as they push toward potential commercialization. These aren't just line items; they are the tangible and intangible foundations supporting their rare disease strategy.

Ersodetug (RZ358) stands as the lead asset, a fully human monoclonal antibody designed to treat hypoglycemia caused by hyperinsulinism (HI) across all forms, including congenital and tumor-induced. The clinical progress itself translates directly into resource value, especially given the severe unmet need; for instance, 60% of patients on first-line diazoxide for HI fail to respond to it.

The value of the drug is significantly enhanced by its regulatory status, which acts as a powerful proxy for the strength of the underlying intellectual property protecting the mechanism and use. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for ersodetug for two distinct indications:

• Hypoglycemia due to congenital HI.
• Hypoglycemia due to tumor HI, granted in May 2025.

The tangible financial resource supporting this development and the build-out of commercial readiness is the balance sheet strength as of the end of the fiscal year. Here's the quick math on their liquidity:

The specialized personnel are critical for executing the late-stage trials and preparing for launch. This includes clinical development experts managing the ongoing studies and commercial leaders. The increased headcount is evident in the rising G&A expenses.

Key personnel resources include:

• The executive team, including Chief Executive Officer and Founder Nevan Charles Elam.
• Appointment of Dr. Sunil Karnawat as Chief Commercial Officer to lead launch strategy.
• Specialized staff driving clinical trial activities, reflected in R&D expenditure increases.

The progress in the Phase 3 trials directly relates to the perceived value of these resources. Enrollment for the congenital HI sunRIZE trial was completed with 62 participants, exceeding the target, with topline results anticipated in December 2025. For tumor HI, FDA alignment allowed for a streamlined Phase 3 (upLIFT) study, requiring as few as 16 participants, with results expected in the second half of 2026.

Rezolute, Inc. (RZLT) - Canvas Business Model: Value Propositions

First-in-class, non-surgical treatment for congenital hyperinsulinism (cHI).

Potential universal efficacy for all forms of HI by acting downstream of the pancreas. Ersodetug acts downstream from the pancreas, giving it the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI.

Addressing a high unmet need where first-line therapy (diazoxide) fails in over 50% of patients. The only approved therapy, diazoxide, is unable to work in more than half of patients. Furthermore, 60% of patients taking first-line diazoxide for hypoglycemia due to HI fail to respond to it.

The persistent unmet need in the congenital HI population, as reflected in the sunRIZE trial enrollment, includes:

• Birth prevalence of cHI is approximately 1 in 28,000 live births in the US, equating to about 130 new patients per year.
• 50% of children with cHI have neurological deficiencies caused by hypoglycemic lows.

Streamlined development path for tumor HI, reducing time to market. The Company achieved alignment with the FDA in August 2025 on a significantly streamlined clinical development path for the Phase 3 upLIFT study in tumor HI.

This regulatory outcome translates to specific development efficiencies:

• The truncated study will include as few as 16 participants.
• The design removes the need to conduct a double-blind randomized placebo-controlled trial.
• The pivotal sunRIZE trial in congenital HI will serve as confirmatory clinical evidence for the tumor HI indication.
• Topline results for the upLIFT study are expected in the second half of 2026.

The Company reported cash, cash equivalents and investments of $88.4 million as of March 31, 2025, followed by a $\approx$$97 million equity financing in April 2025, extending the cash runway to the middle of 2027. Full fiscal year 2025 Research and development expenses were $61.5 million.

Rezolute, Inc. (RZLT) - Canvas Business Model: Customer Relationships

You're hiring before product-market fit, so your customer relationships are currently focused on the clinical community and the investment base funding the path to market. Rezolute, Inc. is clearly leaning into a high-touch model given the rare disease focus and the complexity of hyperinsulinism (HI).

The engagement with the clinical community is evidenced by the execution of global, pivotal trials. The sunRIZE Phase 3 study for congenital HI completed enrollment with 62 participants, with topline results anticipated in December 2025. This required close collaboration with investigators across sites in more than a dozen countries. Furthermore, the streamlined Phase 3 upLIFT study for tumor HI is set to enroll as few as 16 participants, indicating a focused, direct relationship with a small, specialized investigator group for that indication.

The profile of the patients in the completed enrollment for the sunRIZE trial gives you a concrete look at the patient population Rezolute is engaging with and whose treating physicians (KOLs/endocrinologists) are central to their relationship strategy:

The planning for post-commercialization patient support is signaled by organizational structure. Rezolute, Inc. appointed Dr. Sunil Karnawat as Chief Commercial Officer to lead the launch strategy for ersodetug. This move suggests a direct relationship strategy for patients and prescribers upon approval, likely involving dedicated support programs, though specific program enrollment or budget figures for these are not yet public.

Investor relations is managed through transparent updates tied directly to these clinical milestones. The company ended the fiscal year ended June 30, 2025, with $167.9 million in cash, cash equivalents, and investments. This financial strength, extended by an approximate $97 million financing in April 2025, provides a runway to the middle of 2027, assuring investors of funding through key data readouts like the December 2025 sunRIZE topline data. Public updates detail the financial commitment to this relationship-building through R&D spend, which was $61.5 million for the full fiscal year 2025.

Key investor relations touchpoints and milestones reported as of late 2025 include:

• Topline results from sunRIZE trial expected in December 2025.
• Topline results from upLIFT trial expected in 2H 2026.
• Target for Biologics License Application (BLA) filing is mid-2026.
• The company reported a net loss of $74.4 million for the full fiscal year 2025.
• The Q4 fiscal 2025 non-GAAP EPS loss was $(0.26).

The company is definitely focused on keeping its financial stakeholders informed.

Rezolute, Inc. (RZLT) - Canvas Business Model: Channels

You're looking at how Rezolute, Inc. (RZLT) plans to get ersodetug to patients, which is key since they are a rare disease company preparing for potential launch. The channel strategy is clearly bifurcated between ongoing clinical execution and future commercial readiness.

For the planned post-approval phase, Rezolute, Inc. is banking on a US self-commercialization model for ersodetug, which is typical for specialized rare disease products where high-touch patient support is necessary. This commercial readiness was signaled by the appointment of Dr. Sunil Karnawat as Chief Commercial Officer in August 2025, bringing experience from launching four ultra-rare disease products at Ultragenyx. The ex-US strategy is more flexible, aiming to balance distribution with potential partnering across regions like Europe and the Middle East.

The current channels are defined by the active clinical trial network, which is essential for gathering the data needed for regulatory submission. The sunRIZE trial for congenital hyperinsulinism (HI) has completed enrollment with 62 participants. For the tumor HI indication, the streamlined upLIFT Phase 3 study is designed for as few as 16 participants.

Here's a quick look at the current clinical channel footprint:

Data dissemination, a critical channel for scientific validation and physician awareness, is heavily focused on near-term milestones. The company presented preliminary patient demographics from the sunRIZE trial at a major medical meeting.

• Presentation of Preliminary Patient Demographics at ENDO 2025.
• Topline results for the sunRIZE trial are expected in December 2025.
• Topline results for the upLIFT trial are expected in the second half of 2026.

The investment in the commercial channel infrastructure is reflected in the General and Administrative (G&A) expenses, which reached $18.4 million for the full fiscal year 2025, up from $14.7 million in fiscal year 2024, partly due to increased headcount. The company's cash position of $167.9 million as of June 30, 2025, is intended to support this transition toward launch readiness.

Rezolute, Inc. (RZLT) - Canvas Business Model: Customer Segments

Ultra-rare disease patients with Congenital Hyperinsulinism (cHI)

The target population for the sunRIZE Phase 3 study, which completed enrollment in May 2025, included 62 participants globally, with approximately 15 percent from U.S. sites.

Epidemiological estimates for the broader cHI population include:

• Minimum birth prevalence in Norway: 1 in 19,400 live births.
• Estimated prevalence in Brazil: approximately 3 in 100,000 live births.
• Best estimate for persistent HI in European-ancestry populations: 3.5 per 100,000 births.
• Reported overall birth prevalence in some studies: 21.0 per 100,000 births (2000-2015).
• General occurrence reported: approximately 1 in 28,000 births in most countries.

The profile of the sunRIZE enrolled population as of the end of fiscal year 2025 (June 30, 2025) showed:

Topline results from this cHI trial are anticipated in December 2025.

Rare disease patients with Tumor Hyperinsulinism (tHI) (e.g., insulinoma)

Rezolute, Inc. advanced its registrational upLIFT study for tumor HI mid-year 2025, following FDA Breakthrough Therapy Designation granted in May 2025.

The streamlined Phase 3 upLIFT study, aligned with the FDA in August 2025, is planned to include as few as 16 participants.

Pediatric endocrinologists and metabolic disease specialists

This group includes specialists who manage the 62 participants enrolled in the sunRIZE trial, which included 35% under the age of 2 years old.

The company's operational scale as of June 30, 2025, involved expenditures supporting these clinical efforts:

• Full fiscal year 2025 Research and Development expenses: $61.5 million.
• Full fiscal year 2025 General and Administrative expenses: $18.4 million.
• Cash, cash equivalents and investments as of June 30, 2025: $167.9 million.

These specialists are the prescribers and monitors for patients with both congenital and acquired forms of hyperinsulinism.

Caregivers and families managing chronic, severe hypoglycemia

This segment is directly impacted by the 15 average hypoglycemia events per week experienced by the sunRIZE trial population.

The burden on families is underscored by the fact that 95% of the enrolled cHI patients required $\ge 1$ Standard of Care (SOC) treatments.

The company's full fiscal year 2025 net loss was $74.4 million, reflecting the investment required to develop a therapy for this severely affected patient group.

Rezolute, Inc. (RZLT) - Canvas Business Model: Cost Structure

You're looking at the spending side of Rezolute, Inc. as they push ersodetug toward potential commercialization. The costs are heavily weighted toward late-stage clinical development and building out the necessary infrastructure. For the fiscal year ended June 30, 2025, the company's total operating expenses hit $79.9 million.

The primary cost drivers fall squarely within Research and Development (R&D) and General and Administrative (G&A) functions, reflecting the biopharma stage of the business. Research and Development expenses for the full fiscal year 2025 were $61.5 million, up from $55.7 million in fiscal year 2024.

General and Administrative expenses for fiscal year 2025 totaled $18.4 million, a 25% increase from the $14.7 million reported in fiscal year 2024. This rise was mainly due to professional fees and employee-related costs associated with an increased headcount.

Here's a breakdown of where the money went in fiscal year 2025:

Clinical trial costs for the ersodetug program were a major component of the R&D spend. The Ersodetug Program Costs specifically increased by $11.8 million year-over-year. This spending supports both the congenital HI and tumor HI indications.

The clinical trial activities included:

• Completing enrollment in the sunRIZE Phase 3 study with 62 participants.
• Progressing the upLIFT Phase 3 study for tumor HI, which was streamlined to include as few as 16 participants.
• Clinical costs for the tumor HI Phase 3 study accounted for $3.2 million of the Ersodetug Program Cost increase.

Manufacturing and scale-up costs for commercial drug supply also factored into the R&D increase. Specifically, manufacturing costs for ersodetug related to the tumor HI Phase 3 study were $6.7 million.

Personnel expenses drove increases across both functional areas. As of June 30, 2025, Rezolute, Inc. had 71 full-time employees, with 52 engaged in research and development and 19 in general and administrative functions. G&A Compensation and Benefits increased by $1.8 million, tied to higher average headcount and performance bonuses.

The company also made strategic hires to prepare for a potential launch, appointing a Chief Commercial Officer in August 2025.

Rezolute, Inc. (RZLT) - Canvas Business Model: Revenue Streams

As of the end of fiscal year 2025, Rezolute, Inc. remains a pre-commercial entity, meaning product sales have not yet begun to generate top-line revenue.

For the full fiscal year ended June 30, 2025, Rezolute, Inc. reported USD 0 in revenue.

The current financial position supports ongoing operations and preparations for potential future revenue streams. Rezolute, Inc. reported cash, cash equivalents, and investments in marketable securities totaling $167.9 million as of June 30, 2025. This balance is the source of any current interest income the company may realize.

Future revenue generation is entirely contingent on the successful regulatory approval and subsequent commercialization of ersodetug for hypoglycemia due to hyperinsulinism. The company is actively preparing for this, having appointed Dr. Sunil Karnawat as Chief Commercial Officer in August 2025 to spearhead the launch strategy.

A significant component of the potential future financial structure involves milestone payments owed to prior partners, XOMA and ActiveSite, upon clinical and commercial success. These obligations are detailed below:

The total potential milestone payments tied to future commercialization and alternative indication regulatory approvals for ersodetug and RZ402 amount to up to $202.5 million payable to XOMA and ActiveSite combined, in addition to the initial clinical/regulatory milestones. It is important to note that none of these future payments may ever be required if commercialization is not achieved.

The near-term focus for a potential revenue catalyst is the expected reporting of topline results from the sunRIZE trial in December 2025.

• Fiscal Year 2025 Product Revenue: $0
• Cash and Investments as of June 30, 2025: $167.9 million
• Total Potential Future Milestones (Sales/Indication): Up to $202.5 million
• Fiscal Year 2025 Net Loss: $74.4 million